Relapse-free survival (RFS) analysis in 46 patients with early-stage disease treated with potentially curative surgery and for whom follow-up data were available showed a significantly worse RFS in patients with tumours showing MCT4 staining intensities of 3 or 4 (Figure 5E, p = 0.017). Here, SLC16A3 is linked to neoplasm.